FTSE 100 today: Index rises, pound strengthens; Tullow Oil slumps, Hiscox rises
Jeffrey William Henderson, a director at Halozyme Therapeutics , Inc. (NASDAQ:HALO), recently sold shares of the company’s stock in transactions that took place on March 3, 2025. The sales were executed under a pre-established trading plan in compliance with Rule 10b5-1, adopted on September 17, 2024. According to InvestingPro data, HALO has demonstrated strong financial health with a perfect Piotroski Score of 9, while the stock has gained over 21% year-to-date.
Henderson sold a total of 5,000 shares, with transactions split into two separate sales. The first sale involved 1,795 shares at a weighted average price of $57.934 per share, while the second sale comprised 3,205 shares at a weighted average price of $59.116 per share. The shares were sold at prices ranging from $57.73 to $59.57, resulting in a total transaction value of $293,458. Notably, InvestingPro analysis suggests the stock is currently trading below its Fair Value, with 12 additional ProTips available to subscribers.
Following these transactions, Henderson holds 33,611 shares of Halozyme Therapeutics. Despite this insider sale, the company’s management has been actively buying back shares, and the stock maintains strong fundamentals with a healthy current ratio of 7.8x and robust revenue growth of 22.4% over the last twelve months.
In other recent news, Halozyme Therapeutics reported strong financial results for the fourth quarter and the full year 2024, with total revenue reaching $1.015 billion, marking a 22% increase from the previous year. The company achieved adjusted earnings per share of $1.26 for the fourth quarter, surpassing analyst estimates of $1.15, while revenue for the quarter came in at $298 million, exceeding the consensus forecast of $294.15 million. Halozyme’s royalty revenue, driven by products like DARZALEX SC, VYVGART Hytrulo, and Phesgo, surged 40% to $170.4 million in the fourth quarter.
JMP Securities responded to these results by raising their price target for Halozyme shares from $73.00 to $78.00, maintaining a Market Outperform rating. H.C. Wainwright also lifted their price target to $72 from $70, reiterating a Buy rating. Both firms highlighted the company’s robust royalty streams and the impact of its share repurchase program as positive factors.
Looking forward, Halozyme has provided an optimistic forecast for 2025, projecting total revenue between $1.15 billion and $1.225 billion, with expected adjusted earnings per share ranging from $4.95 to $5.35. The company emphasized its confidence in continued growth, supported by recent regulatory approvals for products using its ENHANZE technology. Analysts at JMP Securities anticipate about $745 million in royalties for 2025, marking a projected 30% year-over-year growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.